Omneity® Pellets
All-In-One Vitamin & Mineral Pellet
Topic:Immunization
Immunization in horses involves the administration of vaccines to stimulate an immune response, thereby providing protection against specific infectious diseases. Vaccines commonly used in equine medicine include those for equine influenza, tetanus, and West Nile virus. The process of immunization aims to prepare the horse's immune system to recognize and combat pathogens upon exposure. Vaccination schedules and protocols may vary based on factors such as age, health status, and regional disease prevalence. This page compiles peer-reviewed research studies and scholarly articles that explore the mechanisms, efficacy, and considerations of immunization practices in equine health.
Comparison of immunization methods for producing reference adenovirus antisera in horses. Horses were immunized by a variety of inoculation procedures designed to determine the most efficient method of producing antisera to adenovirus types 25 to 31. The procedures evaluated included immunization by (i) direct intravenous (iv) injection, (ii) iv infusion, (iii) intramuscular (im) injection of virus with and without Freund's incomplete adjuvant, (iv) combined iv and im injections, and (v) combined iv infusion and im injection. The im schedule (no. 3) was superior to the others in terms of immunizing antigen and time required, and hemagglutination-inhibition (HI) and serum-neutralizi...
Preparation and evaluation of inactivated Venezuelan equine encephalitis vaccines. No abstract available
Experimental infection of horses with an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83). Ten horses (Equus caballus) were vaccinated with strain TC-83 Venezuelan equine encephalomyelitis (VEE) virus vaccine. Febrile responses and leukopenia due to a reduction of lymphocytes and neutrophils were observed in all animals. Viremias were demonstrable in eight horses, with a maximum of 10(3.5) median tissue culture infectious dose units per ml of serum in two horses. Clinical illness with depression and anorexia were observed in five horses. Neutralizing (N), hemagglutination-inhibiting, and complement-fixing antibodies to the vaccine virus were demonstrable by 5, 6.5, and 7 days, respe...
Tolerance to sheep red cells: breakage with thymocytes and horse red cells. Mice rendered tolerant to sheep red cells and then given normal thymocytes, made no antibody when immunized with these cells. When immunized with horse red blood cells, however, they made significant amounts of noncross-reacting antibody to sheep red blood cells. This suggests that antibody-making precursor cells (B cells) which are nontolerant but nonactivatable by specific antigen, may exist in tolerant hosts.
Field studies of an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83). A series of field studies using strain TC-83 attenuated Venezuelan equine encephalomyelitis vaccine in horses was made to determine the rate of seroconversions, the postvaccination viremia, and the possibility of adverse reactions to the vaccine. The rate of seroconversions varied from 50% in one study to 91 and 100% in two others. The highest level of viremia measured was 7 x 10(3) to 8 x 10(3) plaqueforming units per ml. No adverse reactions to the vaccine were observed in any horses, including 42 pregnant mares and their resulting foals.
Preparation and standardization of an Australia antigen antibody of equine origin. A horse has been immunized with Australia antigen (Au/SH) purified 20-fold by a procedure employing gel filtration of Cohn fraction IV derived from an Au/SH-positive human plasma pool. Hyperimmunization was initiated by the intramuscular injection of 20 ml of a mixture of equal parts of purified Au/SH and complete Freund's adjuvant. The 20-ml volume was divided into four 5-ml doses, two of which were administered on each side of the horse's neck. Booster doses of antigen alone were given as follows: 10 ml intravenously 30 days later and 5 ml intramuscularly on each of days 77 and 205. Au/SH an...
Heat-labile factor necessary for hemagglutination-inhibition testing of horse sera. Normal and immune sera were obtained from horses immunized with either aqueous, alum, or adjuvant bivalent vaccines containing Milford equine 2 virus. Upon heating at 56 C for 30 min, a factor, required for hemagglutination-inhibition but not complement fixation or neutralization testing, was destroyed. This factor which is present in normal sera does not appear to be complement.
Immunogenicity of purified venezuelan equine encephalitis virus inactivated by ionizing radiation. Purified and concentrated Venezuelan equine encephalitis (VEE) virus derived from tissue cultures, rendered noninfectious by ionizing radiation with retention of in vitro serological activity, also retained a high level of immunogenicity. In mice, fluid vaccines afforded excellent protection against lethal challenge with homologous Trinidad strain VEE virus. A direct relationship was observed between concentration of vaccine or number of injections and survival. One intraperitoneal inoculation of undiluted vaccine protected essentially all mice challenged 21 days later with 100,000 mouse intra...
Monospecific equine antiserum against cholera exo-enterotoxin. An antiserum specific for Vibrio cholerae exo-enterotoxin was produced by immunization of a horse with purified choleragenoid, a natural cholera toxoid. The serum has a high titer against the toxin antigen in passive hemagglutination tests and a respectable antipermeability factor activity. It also passively protected against choleragen-induced mouse foot edema. The serum was found to be useful for assaying toxin antigen in crude and refined products by in vitro tests such as radial immunodiffusion, Lf, and quantitative precipitin titrations. Based upon experimental observations, the serum was...
The development and distribution of antilymphocytic and other antibodies in horses immunized with human lymphoid antigens. Serum samples were obtained at regular intervals from groups of horses immunized with peripheral blood lymphocytes, thoracic duct lymphocytes, or peripheral blood lymphocyte membranes. These sera were separated into the classical 19 S, 10 S, 7 S, and 4.5 S fractions by Sephadex gel filtration and the antibody activity (antilymphocytic or otherwise) of these fractions, and of the original sera, was assessed by standard in vitro procedures. The antilymphocytic activities measured included lymphocyte agglutination, lysis, and transformation. The other antibodies assayed were platelet and erythroc...
